|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
WO2000075184A1
(en)
*
|
1999-06-04 |
2000-12-14 |
Yale University |
Modulation of protein levels using the scf complex
|
|
KR20120099462A
(ko)
|
2009-11-12 |
2012-09-10 |
더 리젠츠 오브 더 유니버시티 오브 미시건 |
스피로-옥신돌 ｍｄｍ2 길항제
|
|
US8088815B2
(en)
|
2009-12-02 |
2012-01-03 |
Hoffman-La Roche Inc. |
Spiroindolinone pyrrolidines
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
JO2998B1
(ar)
|
2010-06-04 |
2016-09-05 |
Amgen Inc |
مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
|
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
|
SI2958893T1
(sl)
|
2013-02-21 |
2017-08-31 |
F. Hoffmann-La Roche Ag |
Asimetrična sinteza substituiranega pirolidin-2-karboksamida
|
|
CN105358530A
(zh)
|
2013-06-10 |
2016-02-24 |
美国安进公司 |
制备mdm2抑制剂的方法及其结晶形式
|
|
EP3013316B1
(en)
|
2013-06-24 |
2018-05-30 |
F.Hoffmann-La Roche Ag |
Stable intravenous formulation
|
|
BR112015031542A2
(pt)
*
|
2013-07-03 |
2017-07-25 |
Hoffmann La Roche |
métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores
|
|
KR102272536B1
(ko)
|
2013-09-04 |
2021-07-02 |
다이이찌 산쿄 가부시키가이샤 |
스피로옥시인돌 유도체의 제조 방법
|
|
ES2883289T3
(es)
|
2013-12-20 |
2021-12-07 |
Astex Therapeutics Ltd |
Compuestos heterocíclicos bicíclicos y sus usos en terapia
|
|
ES2712973T3
(es)
|
2014-04-17 |
2019-05-17 |
Univ Michigan Regents |
Inhibidores de MDM2 y métodos terapéuticos que usan los mismos
|
|
WO2016059241A2
(en)
*
|
2014-10-17 |
2016-04-21 |
Biomirna Holdings Ltd. |
Lung cancer diagnostics and therapeutics with mir-660
|
|
GB201517216D0
(en)
|
2015-09-29 |
2015-11-11 |
Cancer Res Technology Ltd And Astex Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201517217D0
(en)
|
2015-09-29 |
2015-11-11 |
Astex Therapeutics Ltd And Cancer Res Technology Ltd |
Pharmaceutical compounds
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
WO2017176958A1
(en)
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
WO2017205786A1
(en)
|
2016-05-27 |
2017-11-30 |
Aileron Therapeutics, Inc. |
Cell permeable peptidomimetic macrocycles
|
|
GB201704965D0
(en)
|
2017-03-28 |
2017-05-10 |
Astex Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201919219D0
(en)
|
2019-12-23 |
2020-02-05 |
Otsuka Pharma Co Ltd |
Cancer biomarkers
|